No abstract available.
Pyrazoles ; Sulfonamides ; Celecoxib

No abstract available.
Primary Myelofibrosis ; Pyrazoles ; Transplants

OBJECTIVETo establish a high-performance liquid chromatography (HPLC)-based method for determining celecoxib concentration in the tongue tissue of hamsters.

METHODSCelecoxib mixed with the matrix (final concentration of 6%) was smeared on the surface of the tongue mucosa of hamsters, and the concentration and absorption rate of celecoxib in the tongue tissue were determined by HPLC at 5, 10, 15, 30, 60, 90, 120 min after the application.

RESULTSIn this system, the retention time of celecoxib was 4.4 min. Celecoxib concentration showed a good linear range within 25-800 microg/L (R2=0.9991, n=6), with the detection limit for celecoxib of 10 g/L (S/N=3). The extraction recoveries and method recoveries for celecoxib were 83.75%-90.01% and 91.98%-99.07%, respectively. The inter-day RSDs were 2.15%, 3.16% and 3.67%, and intra-day RSDs were 3.40%, 4.56% and 4.42%, respectively. The concentration of celecoxib in hamster tongue tissue within the first 120 min ranged from 0.685-/+0.019 microg/g to 3.168-/+0.143 g/g, reaching the peak level at 15 min.

CONCLUSIONCelecoxib can be rapidly absorbed through the tongue mucosa to reach a high concentration in the tongue tissue, indicating the possibility of oral COX-2 inhibitors to prevent oral cancer and precancerous lesions.

Animals ; Celecoxib ; Chromatography, High Pressure Liquid ; methods ; Cricetinae ; Pyrazoles ; analysis ; pharmacokinetics ; Sulfonamides ; analysis ; pharmacokinetics ; Tongue ; metabolism

OBJECTIVETo observe whether Celecoxib could inhibit the growth, regulate the expression of COX-2 and induce apoptosis of Tca8113 cells.

METHODSTca8113 cells were incubated with different concentrations of Celecoxib for 24, 48 and 72 h, and MTT was used to calculate growth inhibition rate. The expression of COX-2 protein and mRNA in Tca8113 cells was detected with SP immunohistochemistry staining and fluorescent quantitative real-time RT-PCR. Morphology of apoptosis cells was observed by fluorescence microscopy, and Annexin V-FITC/PI double labeling method was employed to detect early stage cell apoptosis.

RESULTSCOX-2 protein was strongly expressed in Tca8113 cells and was suppressed by Celecoxib. The growth and proliferation of Tca8113 cells treated with Celecoxib were inhibited in a dose-dependent manner. Celecoxib treatment resulted in significant increase in apoptosis and early apoptotic rate. Fluorescent quantitative real-time RT-PCR results showed no significant effet on regulating expression of COX-2 mRNA.

CONCLUSIONCelecoxib shows a significant effect on inhibiting expression of COX-2 in Tca8113 cells, this is probably related to growth inhibition and inducing apoptosis of Tca8113 cells.

Apoptosis ; Celecoxib ; Cell Line ; Cell Line, Tumor ; Cell Proliferation ; Cyclooxygenase 2 ; Humans ; Pyrazoles ; Sulfonamides

Acute generalized exanthematous pustulosis (AGEP) is manifested by rapid development of many sterile, nonfollicular pustules on a background of edematous erythema. More than 90 percent of AGEP are induced by medication, mostly antibiotics. Drug patch test can be helpful in the diagnosis of AGEP. This paper reports the first case of celecoxib-induced AGEP confirmed by patch test in Korean literature.
Acute Generalized Exanthematous Pustulosis ; Anti-Bacterial Agents ; Erythema ; Patch Tests ; Pyrazoles ; Sulfonamides ; Celecoxib

No abstract available.
Benzydamine* ; Hallucinations*

Acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs), which reduce the production of prostaglandin by inhibiting cyclooxygenase (COX), are widely used in children as antipyretic, analgesic, or anti-inflammatory drugs. They are known to be a major cause of pediatric drug allergies, which are diagnosed by a drug provocation test. The mechanism comprises an immunoglobulin E- or T cell-mediated immune reaction or pseudoallergy caused by the inhibition of COX-1. The diagnosis of NSAIDs drug allergy requires a differential, because there is a high cross-reactivity between NSAIDs. In this study, oral provocation tests with ibuprofen, acetaminophen, diclofenac and celecoxib were carried out, and various types of NSAIDs and acetaminophen allergies were observed. Safe drugs were recommended for each patient according to the test results. We report four cases of NSAIDs and acetaminophen allergy and include the results of oral provocation tests.
Acetaminophen ; Anti-Inflammatory Agents, Non-Steroidal ; Child ; Diclofenac ; Drug Hypersensitivity ; Humans ; Hypersensitivity ; Ibuprofen ; Immunoglobulins ; Prostaglandin-Endoperoxide Synthases ; Pyrazoles ; Sulfonamides ; Celecoxib

BACKGROUND: For laparoscopic cholecystectomy, pain is most frequent complaint and the most common cause of delayed discharge. The aim of this study was to determine the effect of preoperative administration of celecoxib on the level of postoperative pain in patient undergoing laparoscopic cholecystectomy. METHODS: We enrolled 60 patients ASA class I and II, scheduled for elective laparoscopic cholecystectomy. The patients were randomized to receive celecoxib 200 mg, celecoxib 400 mg or placebo two hour before the induction of anesthesia. The patients received the same anesthetics. The intensities of abdominal pain were assessed using VAS (visual analog scale) at 1, 2, 4, 12, 24 hours after surgery. RESULTS: In celecoxib 200 mg group, VAS score of somatic pain compared to control group decreased at 1, 2, and 4 hours after surgery. In celecoxib 400 mg group, VAS score of somatic pain compared to control group decreased at 1, 2, and 4 hours after surgery. There was no difference between celecoxib 200 mg and celecoxib 400 mg in pain scores of somatic pain. Dosage of meperidine in two celecoxib groups after surgery were each 31 mg and 26 mg and that of control group was 72 mg. There was no difference between celecoxib groups and placebo group in pain scores of visceral pain. CONCLUSIONS: The preoperative administration of celecoxib reduces the level of postoperative pain after laparoscopic cholecystectomy without adverse effects.
Abdominal Pain ; Anesthesia ; Anesthetics ; Cholecystectomy, Laparoscopic ; Humans ; Meperidine ; Nociceptive Pain ; Pain, Postoperative ; Pyrazoles ; Sulfonamides ; Visceral Pain ; Celecoxib

OBJECTIVETo evaluate the efficacy and safety of celecoxib in treating inflammatory(Type IIIA) chronic prostatitis/chronic pelvic pain syndrome(CP/CPPS-IIIA type).

METHODSSixty-four patients with diagnosed CP/CPPS-IIIA were randomized equally into two groups, Group A treated with celecoxib 200 mg daily(qd), while Group B with 200 mg twice a day(bid), both for 6 weeks. The white blood cell (WBC) count in expressed prostate secretion(EPS) and National Institutes of Health Chronic Prostatitis Symptom Index(NIH-CPSI) were assessed and compared at baseline(0 week) and at 2, 4, 6 weeks or the endpoint.

RESULTSThe mean number of WBC in EPS and the mean NIH-CPSI total scores were decreased gradually after treatment from baseline in both groups. The mean number of WBC of in EPS of either group at the endpoint was decreased by 46.2% and 69.4% respectively(Group A vs Group B) compared with the baseline level. The mean NIH-CPSI total scores of the two groups were decreased respectively by 5.6 and 8.3 points (Group A vs Group B). In terms of the above two parameters, Group B, responded better than Group A to the treatment. The differences observed above were statistically significant(all P < 0.05). No serious adverse event presented.

CONCLUSIONCelecoxib is effective and safe for patients with CP/CPPS(IIIA). The dosage of 200 mg twice a day is more efficacious than that of 200 mg daily.

Adult ; Celecoxib ; Chronic Disease ; Cyclooxygenase Inhibitors ; therapeutic use ; Humans ; Male ; Middle Aged ; Prostatitis ; drug therapy ; Pyrazoles ; Sulfonamides ; therapeutic use

OBJECTIVETo investigate the effect of celecoxib on adhesion, invasion, migration and matrix metalloproteinase-2(MMP-2) expression of tongue squamous cell carcinoma cell line Tca8113 cells.

METHODSFollowing incubation with celecoxib, the Tca8113 cells were detected for cell adhesion and migration using cell adhesion assay and Boyden chamber invasion assay. The expression of cyclooxygenase-2 (Cox-2) protein in Tca8113 cells was tected with SP immunohistochemistry staining. The MMP-2 level in supernatant was detected with enzyme-linked immunosorbent assay. RESULTS; The adhesion and Boyden chamber invasion assays showed that, after treatment celecoxib, the ability of adhesion and migration of Tca8113 cells was significantly inhibited. Celecoxib could decrease the expression of Cox-2 protein in Tca8113 cell and decrease the MMP-2 level in supernatant.

CONCLUSIONCox-2 inhibitor celecoxib can significantly inhibit the adhesion and migration of Tca8113 cells. The inhibitory effect on hesion and migration may be correlative with its effect on decrese of Cox-2 protein expression and secretion MMP-2 in Tca8113 cells.

Carcinoma, Squamous Cell ; Celecoxib ; Cell Adhesion ; Cell Line, Tumor ; Cyclooxygenase 2 Inhibitors ; Humans ; Matrix Metalloproteinase 2 ; Pyrazoles ; Sulfonamides ; Tongue Neoplasms